SAN

85.43

-0.78%↓

MRK1

110.15

-0.59%↓

ARGX

803.6

+0.6%↑

PHIA

23.38

-0.38%↓

ONC.US

349.43

-0.74%↓

SAN

85.43

-0.78%↓

MRK1

110.15

-0.59%↓

ARGX

803.6

+0.6%↑

PHIA

23.38

-0.38%↓

ONC.US

349.43

-0.74%↓

SAN

85.43

-0.78%↓

MRK1

110.15

-0.59%↓

ARGX

803.6

+0.6%↑

PHIA

23.38

-0.38%↓

ONC.US

349.43

-0.74%↓

SAN

85.43

-0.78%↓

MRK1

110.15

-0.59%↓

ARGX

803.6

+0.6%↑

PHIA

23.38

-0.38%↓

ONC.US

349.43

-0.74%↓

SAN

85.43

-0.78%↓

MRK1

110.15

-0.59%↓

ARGX

803.6

+0.6%↑

PHIA

23.38

-0.38%↓

ONC.US

349.43

-0.74%↓

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

20.45 0.49

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.3

Max

20.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.4M

46M

Pardavimai

34M

476M

P/E

Sektoriaus vid.

17.436

106.172

Dividendų pajamingumas

1.69

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

16M

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.69%

2.31%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

49M

1.5B

Ankstesnė atidarymo kaina

19.96

Ankstesnė uždarymo kaina

20.45

Naujienos nuotaikos

By Acuity

50%

50%

177 / 374 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-19 23:36; UTC

Karštos akcijos

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

2025-11-19 22:13; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

2025-11-19 21:55; UTC

Pagrindinės rinkos jėgos

Amgen Lung Cancer Drug Gets Full Approval From FDA

2025-11-19 21:43; UTC

Įsigijimai, susijungimai, perėmimai

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

2025-11-19 23:55; UTC

Rinkos pokalbiai

Gold Rises on Possible Investment Demand -- Market Talk

2025-11-19 23:54; UTC

Rinkos pokalbiai

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

2025-11-19 23:47; UTC

Uždarbis

Lenovo Group 2Q EPS $2.52 >0992.HK

2025-11-19 23:46; UTC

Uždarbis

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

2025-11-19 23:45; UTC

Uždarbis

Lenovo Group 2Q Rev $20.5B >0992.HK

2025-11-19 23:42; UTC

Rinkos pokalbiai

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

2025-11-19 23:42; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-19 23:41; UTC

Uždarbis

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

2025-11-19 23:41; UTC

Uždarbis

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

2025-11-19 23:40; UTC

Uždarbis

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

2025-11-19 22:55; UTC

Uždarbis

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

2025-11-19 22:41; UTC

Uždarbis

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

2025-11-19 22:30; UTC

Įsigijimai, susijungimai, perėmimai

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

2025-11-19 22:30; UTC

Uždarbis

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

2025-11-19 22:30; UTC

Įsigijimai, susijungimai, perėmimai

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

2025-11-19 22:27; UTC

Įsigijimai, susijungimai, perėmimai

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

2025-11-19 22:08; UTC

Uždarbis

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

2025-11-19 22:00; UTC

Uždarbis

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

2025-11-19 21:58; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

2025-11-19 21:52; UTC

Uždarbis

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

2025-11-19 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-11-19 21:49; UTC

Rinkos pokalbiai
Uždarbis

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

2025-11-19 21:38; UTC

Uždarbis

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

2025-11-19 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Palo Alto Networks to Buy Chronosphere for $3.35B

2025-11-19 21:27; UTC

Įsigijimai, susijungimai, perėmimai

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

2025-11-19 21:24; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

177 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat